| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA1040691 | F | NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay | Plasmodium falciparum | 5,614 | ALA1156829 | organism-based format | Novartis Malaria Screening | |
| 2. | ALA1040692 | F | NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay | Plasmodium falciparum | 5,614 | ALA1156829 | organism-based format | Novartis Malaria Screening | |
| 3. | ALA1040693 | T | NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) | Homo sapiens | 5,614 | ALA1156829 | cell-based format | Novartis Malaria Screening | |
| 4. | ALA1040694 | F | NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested. | 5,614 | ALA1156829 | assay format | Novartis Malaria Screening | ||
| 5. | ALA1789905 | F | NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence. | Plasmodium yoelii | 4,416 | ALA1789904 | organism-based format | Novartis Malaria Screening | |
| 6. | ALA1789906 | F | NOVARTIS: Antimalarial liver stage activity measured as reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells by immuno-fluorescence, and median schizont size at 10uM compound concentration | Plasmodium yoelii | 338 | ALA1789904 | organism-based format | Novartis Malaria Screening | |
| 7. | ALA2028070 | F | MMV: Inhibition of Plasmodium falciparum 3D7 at 5uM compound concentration. | Plasmodium falciparum | 315 | ALA2028040 | organism-based format | MMV Malaria Box | |
| 8. | ALA2028071 | F | MMV: Inhibition of Plasmodium falciparum 3D7 (EC50). | Plasmodium falciparum | 317 | ALA2028040 | organism-based format | MMV Malaria Box | |
| 9. | ALA2028072 | F | MMV: Inhibition of Plasmodium falciparum K1 (EC50). | Plasmodium falciparum | 171 | ALA2028040 | organism-based format | MMV Malaria Box | |
| 10. | ALA2028073 | F | MMV: Inhibition of Trypanosoma cruzi (Tulahuen C4 LacZ) (Chagas in vitro). | Trypanosoma cruzi | 400 | ALA2028040 | organism-based format | MMV Malaria Box | |
| 11. | ALA2028074 | F | MMV: Inhibition of Trypanosoma brucei brucei (Squib 427) (HAT in vitro). | Trypanosoma brucei brucei | 400 | ALA2028040 | organism-based format | MMV Malaria Box | |
| 12. | ALA2028075 | F | MMV: Inhibition of Trypanosoma brucei rhodesiense (STIB 900) (HAT in vitro). | Trypanosoma brucei rhodesiense | 400 | ALA2028040 | organism-based format | MMV Malaria Box | |
| 13. | ALA2028076 | F | MMV: Inhibition of Leishmania infantum (MHOM/MA/BE/67) in vitro. | Leishmania infantum | 400 | ALA2028040 | organism-based format | MMV Malaria Box | |
| 14. | ALA2028077 | T | MMV: Cytotoxicity against human fibroblasts (MRC-5) cells. | Homo sapiens | 400 | ALA2028040 | cell-based format | MMV Malaria Box | |
| 15. | ALA2094261 | F | MMV: Screen against Mtb, single point, non replicating, at 25uM | Mycobacterium tuberculosis | 399 | ALA2094260 | organism-based format | MMV Malaria Box | |
| 16. | ALA2094262 | F | MMV: Screen against Mtb, single point, replicating, at 25uM | Mycobacterium tuberculosis | 399 | ALA2094260 | organism-based format | MMV Malaria Box | |
| 17. | ALA2363023 | F | MMV: Toxicity @ 2.5 uM to newly transformed Schistosoma mansoni somules after 24 h on a scale of 0 (none) - 4 (most) as judged visually: includes short descriptors of effects (PMID:19597541). Caffrey group UCSF. | Schistosoma mansoni | 400 | ALA2363022 | organism-based format | MMV Malaria Box | |
| 18. | ALA2363024 | F | MMV: Toxicity @ 2.5 uM to newly transformed Schistosoma mansoni somules after 48 h on a scale of 0 (none) - 4 (most) as judged visually: includes short descriptors of effects (PMID:19597541). Caffrey group UCSF. | Schistosoma mansoni | 400 | ALA2363022 | organism-based format | MMV Malaria Box | |
| 19. | ALA2363025 | F | MMV: Toxicity @ 2.5 uM to newly transformed Schistosoma mansoni somules after 72 h on a scale of 0 (none) - 4 (most) as judged visually: includes short descriptors of effects (PMID:19597541). Caffrey group UCSF. | Schistosoma mansoni | 400 | ALA2363022 | organism-based format | MMV Malaria Box | |
| 20. | ALA2448810 | F | MMV: Compounds (1uM) were screened in a 72hr growth assay monitored by flow cytometry both in the presence and absence of supplemental isopentenyl pyrophosphate (IPP) 200uM. Compounds which fail to show anti-malarial activity when chemically rescued by IPP are therefore specific to the apicoplast. The values are expressed as the ratio of the corresponding activity with and without IPP, respectively. | Plasmodium falciparum | 400 | ALA2448809 | organism-based format | MMV Malaria Box |
The page will load shortly, Thanks for your patience!